{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:06:18Z","timestamp":1780067178641,"version":"3.54.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.ejphar.2006.09.021","type":"journal-article","created":{"date-parts":[[2006,9,24]],"date-time":"2006-09-24T11:15:32Z","timestamp":1159096532000},"page":"20-30","source":"Crossref","is-referenced-by-count":22,"title":["The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes"],"prefix":"10.1016","volume":"552","author":[{"given":"Sandy","family":"Bour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Carmen","family":"Iglesias-Osma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piedad","family":"Duro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Garcia-Barrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Francisca","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Pr\u00e9vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgile","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Valet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Moratinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Carp\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2006.09.021_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2005.06.042","article-title":"Characterisation of imidazoline I2 binding sites in pig brain","volume":"519","author":"Anderson","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib2","first-page":"R1729","article-title":"Beta 3-adrenoceptor in guinea pig brown and white adipocytes: low expression and lack of function","volume":"271","author":"Atgi\u00e9","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0006-2952(90)90541-R","article-title":"Non-adrenergic sites for imidazolines are not directly involved in the alpha 2-adrenergic antilipolytic effect of UK 14304 in rat adipocytes","volume":"40","author":"Carp\u00e9n\u00e9","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib4","first-page":"681","article-title":"Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites","volume":"272","author":"Carp\u00e9n\u00e9","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1749-6632.1995.tb32427.x","article-title":"Nonadrenergic imidazoline binding sites and amine oxidase activities in fat cells","volume":"763","author":"Carp\u00e9n\u00e9","year":"1995","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF03167058","article-title":"Amine oxidase substrates for impaired glucose tolerance correction","volume":"61","author":"Carp\u00e9n\u00e9","year":"2005","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2006.09.021_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0014-2999(93)90577-5","article-title":"Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site","volume":"230","author":"Chan","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.1995.tb32400.x","article-title":"Pancreatic beta-cells express an imidazoline binding site that is distinct from I1 and I2 sites","volume":"763","author":"Chan","year":"1995","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0891-5849(01)00819-X","article-title":"Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes","volume":"32","author":"Choi","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2006.09.021_bib10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1124\/jpet.105.086926","article-title":"Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose","volume":"315","author":"Claus","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 3","key":"10.1016\/j.ejphar.2006.09.021_bib11","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.2337\/diabetes.51.2007.S448","article-title":"Two generations of insulinotropic imidazoline compounds","volume":"51","author":"Efendic","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2006.09.021_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","article-title":"\u2018Seeing through a glass darkly\u2019: casting light on imidazoline \u2018I\u2019 sites","volume":"19","author":"Eglen","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/0264-6021:3500171","article-title":"Substrates of semicarbazide-sensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor-substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells","volume":"350","author":"Enrique-Tarancon","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2006.09.021_bib14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0028-3908(02)00046-1","article-title":"Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis","volume":"42","author":"Finn","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2006.09.021_bib15","first-page":"409","article-title":"Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?","volume":"28","author":"Holt","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjp.0705986","article-title":"Allosteric modulation of semicarbazide amine oxidase activities in vitro by imidazoline receptor ligands","volume":"143","author":"Holt","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/PL00004911","article-title":"[3H]2-(2-Benzofuranyl)-2-imidazoline, a highly selective radioligand for I2-imidazoline receptor binding sites. Studies in rabbit kidney membranes","volume":"355","author":"Hosseini","year":"1997","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1999.tb09344.x","article-title":"Novel selective compounds for the investigation of imidazoline receptors","volume":"881","author":"Hudson","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.phrs.2005.07.008","article-title":"Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism","volume":"52","author":"Iglesias-Osma","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2006.09.021_bib20","doi-asserted-by":"crossref","first-page":"72S","DOI":"10.1093\/ajh\/5.4.72S","article-title":"Imidazoline binding sites in fat cells. Localization and pharmacologic differentiation from alpha 2-adrenergic receptors","volume":"5","author":"Lafontan","year":"1992","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2006.09.021_bib21","first-page":"876","article-title":"Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites","volume":"37","author":"Langin","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/1357-2725(95)00130-1","article-title":"Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects","volume":"28","author":"Lyles","year":"1996","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0706019","article-title":"Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway","volume":"143","author":"MacInnes","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.bjp.0704579","article-title":"Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine","volume":"135","author":"MacInnes","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0022-3565(24)37382-3","article-title":"Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide","volume":"285","author":"Marti","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/diabetes.50.9.2061","article-title":"Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats","volume":"50","author":"Marti","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2006.09.021_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-2999(02)02473-1","article-title":"Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse","volume":"454","author":"Mayer","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/13543784.8.5.575","article-title":"Imidazoline receptors: new targets for antihyperglycaemic drugs","volume":"8","author":"Morgan","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2006.09.021_bib29","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2174\/1381612013397366","article-title":"Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?","volume":"7","author":"Morgan","year":"2001","journal-title":"Curr. Pharm. Dev."},{"key":"10.1016\/j.ejphar.2006.09.021_bib30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0022-3565(24)29571-9","article-title":"Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes","volume":"297","author":"Morin","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/jpet.102.040592","article-title":"Tyramine stimulates glucose uptake in insulin-sensitive tissues in vitro and in vivo via its oxidation by amine oxidases","volume":"303","author":"Morin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-6147(96)81564-1","article-title":"The elusive family of imidazoline binding sites","volume":"17","author":"Parini","year":"1996","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2006.09.021_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(99)00395-7","article-title":"Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats","volume":"377","author":"Pele-Tounian","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0006-2952(99)00270-1","article-title":"High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance","volume":"58","author":"Pizzinat","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0197-0186(96)00036-8","article-title":"Relationship between imidazoline\/guanidinium receptive sites and monoamine oxidase A and B","volume":"30","author":"Raddatz","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2006.09.021_bib36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0022-3565(24)35399-6","article-title":"Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme","volume":"292","author":"Raddatz","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0014-2999(89)90103-9","article-title":"Imidazolinic radioligands for the identification of hamster adipocyte alpha 2-adrenoceptors","volume":"171","author":"Saulnier-Blache","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00168517","article-title":"An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors","volume":"340","author":"Schulz","year":"1989","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib39","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1074\/jbc.270.17.9856","article-title":"Localization of I2-imidazoline binding sites on monoamine oxidases","volume":"270","author":"Tesson","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2006.09.021_bib40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.103.050468","article-title":"The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X","volume":"306","author":"Velliquette","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00210-005-0024-3","article-title":"Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X","volume":"372","author":"Velliquette","year":"2006","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0014-2999(03)01562-0","article-title":"Inhibition of rat fat cell lipolysis by monoamine oxidase and semicarbazide-sensitive amine oxidase substrates","volume":"466","author":"Visentin","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2005.08.051","article-title":"Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide","volume":"522","author":"Visentin","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib44","first-page":"82","article-title":"Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes","volume":"278","author":"Wang","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2006.09.021_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002109900065","article-title":"3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine","volume":"360","author":"Wiest","year":"1999","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib46","doi-asserted-by":"crossref","first-page":"E634","DOI":"10.1152\/ajpendo.00272.2003","article-title":"Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice","volume":"286","author":"Yu","year":"2004","journal-title":"Am. J. Physiol., Endocrinol Metabol. Gastrointest. Physiol."},{"key":"10.1016\/j.ejphar.2006.09.021_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1196\/annals.1304.044","article-title":"Association between I(2) binding sites and monoamine oxidase-B activity in platelets","volume":"1009","author":"Zhu","year":"2003","journal-title":"Ann. N.Y. Acad. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299906010417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299906010417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:52:07Z","timestamp":1736553127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299906010417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":47,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0014299906010417"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2006.09.021","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}